126 related articles for article (PubMed ID: 6391086)
21. Circulating immune complexes and C3d in human parasitosis.
Verroust PJ; Adam C; Smith MD; Richard-Lenoble D; Kourilsky O; Morel-Maroger LJ
Kidney Int; 1979 Jul; 16(1):9-14. PubMed ID: 575177
[TBL] [Abstract][Full Text] [Related]
22. Determination of circulating immune complexes, C3 and C4 complement components and anti-DNA antibody in different classes of lupus nephritis.
Klein MH; Thorner PS; Yoon SJ; Poucell S; Baumal R
Int J Pediatr Nephrol; 1984 Jun; 5(2):75-82. PubMed ID: 6333404
[TBL] [Abstract][Full Text] [Related]
23. Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity.
Nydegger UE; Zubler RH; Gabay R; Joliat G; Karagevrekis CH; Lambert PH; Miescher PA
J Clin Invest; 1977 May; 59(5):862-8. PubMed ID: 853126
[TBL] [Abstract][Full Text] [Related]
24. Renal transplantation for patients with type I and type II membranoproliferative glomerulonephritis: serial complement and nephritic factor measurements and the problem of recurrence of disease.
Curtis JJ; Wyatt RJ; Bhathena D; Lucas BA; Holland NH; Luke RG
Am J Med; 1979 Feb; 66(2):216-25. PubMed ID: 371395
[TBL] [Abstract][Full Text] [Related]
25. Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis.
Bourke BE; Moss IK; Maini RN
J Immunol Methods; 1982; 48(1):97-108. PubMed ID: 6799579
[TBL] [Abstract][Full Text] [Related]
26. A comparative immunologic study of IgA nephropathy.
Kanatsu K; Doi T; Sekita K; Yoshida H; Nagai H; Hamashima Y
Am J Kidney Dis; 1983 May; 2(6):618-25. PubMed ID: 6342374
[TBL] [Abstract][Full Text] [Related]
27. Comparison of different assays for circulating immune complexes in age matched vasectomized and non-vasectomized men.
Witkin SS; Brandslund I; Svehag SE; Linnet L; møller NP
J Clin Lab Immunol; 1983 Apr; 10(4):193-7. PubMed ID: 6602887
[TBL] [Abstract][Full Text] [Related]
28. Circulating immune complexes following food: delayed clearance in idiopathic glomerulonephritis.
Cairns SA; London A; Mallick NP
J Clin Lab Immunol; 1981 Sep; 6(2):121-6. PubMed ID: 7288868
[TBL] [Abstract][Full Text] [Related]
29. Immune complexes and complement activation following rupture of intracranial saccular aneurysms.
Ostergaard JR; Kristensen BO; Svehag SE; Teisner B; Miletic T
J Neurosurg; 1987 Jun; 66(6):891-7. PubMed ID: 3494822
[TBL] [Abstract][Full Text] [Related]
30. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
Perrin LH; Lambert PH; Miescher PA
J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of plasma C3d and immune complex determinations in the assessment of disease activity of patients with rheumatoid arthritis, systemic lupus erythematosus, and spondylitis ancylopoetica.
Krauledat PB; Krapf FE; Manger B; Kalden JR
Rheumatol Int; 1985; 5(3):97-101. PubMed ID: 3892637
[TBL] [Abstract][Full Text] [Related]
32. Complement components, degradation products and immune complexes after kidney transplantation.
Wegmüller E; Louis J; Hodler J
Proc Eur Dial Transplant Assoc; 1978; 15():289-98. PubMed ID: 368776
[TBL] [Abstract][Full Text] [Related]
33. Serial study of circulating immune complexes before and after renal transplantation.
Johny KV; Dasgupta MK; Kovithavongs T; Dossetor JB
Kidney Int; 1981 Feb; 19(2):332-40. PubMed ID: 7014986
[TBL] [Abstract][Full Text] [Related]
34. Circulating immune complexes in glomerulonephritis.
Solling J; Olsen S
Clin Nephrol; 1981 Aug; 16(2):63-74. PubMed ID: 7021032
[TBL] [Abstract][Full Text] [Related]
35. [Circulating immune complexes before and after kidney allotransplantation].
Keusch G; Vonwiller HM; von Felten A; Bammatter F; Burger HR; Largiadèr F; Binswanger U
Klin Wochenschr; 1984 Apr; 62(8):360-5. PubMed ID: 6374279
[TBL] [Abstract][Full Text] [Related]
36. Determination of the half-life of C3 in patients and its relation to the presence of C3-breakdown products and/or circulating immune complexes.
Swaak AJ; Hannema A; Vogelaar C; Boom FA; van Es L; van Aalst R; Statius van Eps LW
Rheumatol Int; 1982; 2(4):161-6. PubMed ID: 6984977
[TBL] [Abstract][Full Text] [Related]
37. Correlations of C1q- and C3d-bearing circulating immune complexes with immunopathological disease activity in lupus nephritis patients.
Muso E; Yashiro M; Ito Y; Yoshida H; Sasayama S
Nihon Jinzo Gakkai Shi; 1994 Apr; 36(4):345-54. PubMed ID: 8022107
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of serial determinations of circulating immune complex levels in malignant melanoma.
Bukh A; Møller-Larsen A; Aguado MT; Møller-Larsen F; Møller NP
Cancer Immunol Immunother; 1988; 26(3):280-4. PubMed ID: 3260134
[TBL] [Abstract][Full Text] [Related]
39. Complement activation in infective endocarditis: correlation with extracardiac manifestations and prognosis.
Messias-Reason IJ; Hayashi SY; Nisihara RM; Kirschfink M
Clin Exp Immunol; 2002 Feb; 127(2):310-5. PubMed ID: 11876755
[TBL] [Abstract][Full Text] [Related]
40. Circulating immune complexes in idiopathic glomerular disease.
Cairns SA; London RA; Mallick NP
Kidney Int; 1982 Mar; 21(3):507-12. PubMed ID: 6979654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
